We at Renovaro recently returned from BIO 2025 in Boston, where the energy was high, the conversations rich, and the insights invaluable. As we showcased our Neurology and Oncology programs, it became clear just how much the industry has shifted over the past year. The convention floor offered a real-time pulse on where the momentum lies – and where strategic opportunities are emerging.

New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery

We at Renovaro recently returned from BIO 2025 in Boston, where the energy was high, the conversations rich, and the insights invaluable. As we showcased our Neurology and Oncology programs, it became clear just how much the industry has shifted over the past year. The convention floor offered a real-time pulse on where the momentum lies – and where strategic opportunities are emerging.

New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery

We at Renovaro recently returned from BIO 2025 in Boston, where the energy was high, the conversations rich, and the insights invaluable. As we showcased our Neurology and Oncology programs, it became clear just how much the industry has shifted over the past year. The convention floor offered a real-time pulse on where the momentum lies – and where strategic opportunities are emerging.

New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery